Company Overview
Daxor Corporation functions within the healthcare sector, specifically focusing on medical instrumentation and biotechnology operations. The company develops the BVA-100 Blood Volume Analyzer, a specialized instrument designed to measure human blood volume, which operates in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. This entity operates at a market capitalization of $59.09 million and reports trailing twelve-month revenue of $26,688, though the specific employee count is not disclosed in available data. These valuation and revenue figures indicate a small-cap profile with limited scale, suggesting the company targets a niche market rather than competing broadly in the general medical supply industry. The combination of hardware instrumentation and proprietary diagnostic kits positions the firm as a specialized provider of radiopharmaceutical diagnostics.
Financial Health
The company reports trailing twelve-month revenue of $26,688 alongside a net income of $9.17 million, while EBITDA data is not available for this reporting period. The significant gap between the reported revenue and net income reveals an unusual cost structure where net profit vastly exceeds gross revenue, a scenario that requires careful examination of the financial statement classifications. The company generates free cash flow of $100,248, which indicates a specific level of cash generation capability despite the anomalous margin structure. Analysis of the three primary margins shows a gross margin of 100.0%, an operating margin of -9660.6%, and a profit margin of 34359.2%. The 100.0% gross margin suggests that the cost of goods sold is recorded as zero or negative in the reporting system, while the deeply negative operating margin and extremely high profit margin point to significant non-operating income or classification anomalies affecting the bottom line. Comparing total cash and total debt reveals that both metrics are listed as N/A, and the debt-to-equity ratio is also N/A, making it impossible to determine if the balance sheet is conservative or leveraged based on standard leverage metrics. The current ratio stands at 0.08, which indicates severe short-term liquidity constraints as current liabilities significantly exceed current assets. Return on equity is reported at 22.5% while return on assets is -1.6%, revealing a divergence where shareholder equity is generating strong returns despite the assets generating negative returns, a complex dynamic often seen in companies with specific accounting treatments or substantial non-operating gains.
Valuation Assessment
The trailing twelve-month P/E ratio is 6.18, whereas the forward P/E is N/A, implying that analysts do not have a projected earnings trajectory to calculate a forward multiple. The price-to-book ratio is 1.12, which indicates that the market values the company at a slight premium over its book value, suggesting investors value the intangible assets or future potential slightly higher than the recorded net assets. The price-to-sales ratio is an extreme 2214.03, and EV/EBITDA is N/A, suggesting that traditional sales-based and earnings-based valuation multiples are distorted by the unique financial profile of the company. The 52-week high is $14.76 and the 52-week low is $7.10, meaning the stock price fluctuates within a range that defines its recent volatility. The beta value is 0.04, which indicates that the stock's price volatility is significantly lower than the broader market, moving independently of general market trends. These metrics collectively present a valuation picture that is heavily influenced by the company's non-standard earnings and liquidity ratios rather than traditional growth or profitability drivers.
Growth & Income
Revenue growth year-over-year is -82.6%, while earnings growth year-over-year is 329.3%, indicating that earnings are growing significantly faster than revenue, though the revenue contraction masks the underlying profitability mechanics. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the firm reinvests all earnings back into the business or holds cash rather than distributing income to shareholders. This reinvestment strategy aligns with the 0.0% payout ratio, as there is no cash flow being directed toward shareholders but rather retained within the corporate structure. Overall, the growth and income profile is characterized by volatile revenue contraction paired with explosive earnings expansion and a complete absence of dividend income for investors.